Ustekinumab Trough Concentrations Are Associated with Biochemical Outcomes in Patients with Crohn's Disease. Straatmijer T, Biemans VBC, Moes DJAR, Hoentjen F, et al. Dig Dis Sci 2023 Mar 15. doi: 10.1007/s10620-023-07822.

Read + Share

Amedeo Smart

Independent Medical Education

Straatmijer T, Biemans VBC, Moes DJAR, Hoentjen F, et al. Ustekinumab Trough Concentrations Are Associated with Biochemical Outcomes in Patients with Crohn's Disease. Dig Dis Sci 2023 Mar 15. doi: 10.1007/s10620-023-07822.
PMID: 36920666